Cooper Companies
Cooper Companies' revenue rose 5.1% to $4.1 billion in fiscal 2025. Its operating margin was 16.7%, down from 18.1% a year earlier. Free cash flow was $434 million, up 50.5%. It paid out $290 million in dividends and buybacks, 67% of free cash flow. The diluted share count fell 0.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2025, earnings per share grew 3.3% a year and net income 3.5% a year, as new shares raised the share count by 2% and diluted each share's earnings.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Cooper Companies yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Cooper Companies' 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Cooper Companies' fiscal 2025 free cash flow of $434M, net cash of −$2.4B at October 31, 2025 and 200 million diluted shares, from its filings. The scenarios are fitted to Cooper Companies: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 7.3% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 9% for a business of moderate risk (Health Care Supplies); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $61.14
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Cooper Companies' earnings per share of $2.92 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 28×, the middle of Cooper Companies' own P/E today, its peers' median and its sector's median (the Health Care median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 10%, 9% and 8%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $61.14
- Value at this multiple, against the last close
- —
- Cooper Companies' P/E at the last close
- 20.9×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| West Pharmaceutical ServicesWST | $394.73 | $7.81 | 50.5× |
| EnvistaNVST | $23.66 | $0.58 | 40.8× |
| Align TechnologyALGN | $152.26 | $5.74 | 26.5× |
| Cooper CompaniesCOO | $61.14 | $2.92 | 20.9× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 96 | 138 | 121 | 108 | 111 |
| Debt incl. finance leases | 1,398 | 2,763 | 2,569 | 2,584 | 2,505 |
| Net debt (negative means net cash) | 1,302 | 2,625 | 2,448 | 2,476 | 2,395 |
| Net debt to EBITDA | 1.6x | 3.1x | 2.7x | 2.3x | 2.3x |
| Debt to equity | 0.2x | 0.4x | 0.3x | 0.3x | 0.3x |
| Interest coverage | 21.9x | 8.9x | 5.1x | 6.2x | 6.8x |
| Current ratio | 2.0x | 1.2x | 1.8x | 1.9x | 1.9x |
| Quick ratio | 1.2x | 0.7x | 1.0x | 1.1x | 1.1x |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, 7 insiders bought $3.2 million of Cooper Companies shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Lawrence Erik KurziusDirector | Bought | 10,000 | $54.93 | $549,300 | Form 4 |
| Sep 14, 2026 | Lawrence Erik KurziusDirector | Bought | 10,000 | $53.92 | $539,200 | Form 4 |
| Sep 14, 2026 | Walter M Rosebrough JrDirector | Bought | 3,000 | $54.29 | $162,870 | Form 4 |
| Sep 11, 2026 | Walter M Rosebrough JrDirector | Bought | 7,000 | $54.11 | $378,770 | Form 4 |
| Sep 11, 2026 | Paul A KeelDirector | Bought | 4,701 | $53.18 | $250,000 | Form 4 |
| Dec 22, 2025 | Cynthia L LuccheseDirector | Bought | 1,784 | $84.06 | $149,963 | Form 4 |
| Dec 18, 2025 | Maria RivasDirector | Bought | 1,000 | $82.13 | $82,130 | Form 4 |
| Dec 17, 2025 | Lawrence Erik KurziusDirector | Bought | 2,000 | $82.50 | $165,000 | Form 4 |
| Dec 16, 2025 | Albert G White IIIPresident & CEO, Director | Bought | 10,000 | $80.80 | $808,000 | Form 4 |
| Dec 16, 2025 | Holly R SheffieldPresident, Csi | Bought | 1,230 | $80.75 | $99,322 | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 6 of 9 | 8 of 9 | 5 of 9 |
| Accruals ratio | −2.7% | −2.6% | −3.4% |
Compare
Put Cooper Companies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Cooper Companies | FY25 | 5.1% | 16.7% | 10.6% | 4.3% | 2.3x | 5 | |
| Align Technology | FY25 | 0.9% | 13.5% | 12.2% | 13.3% | −1.4x | 5 | Compare |
| Dentsply Sirona | FY25 | −3.0% | −11.5% | 2.8% | −9.9% | — | 6 | Compare |
| West Pharmaceutical Services | FY25 | 6.2% | 19.0% | 15.2% | 18.7% | −0.8x | 9 | Compare |
| Envista | FY25 | 8.3% | 8.0% | 8.5% | 3.2% | 0.7x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1,967 | 2,139 | 2,533 | 2,653 | 2,431 | 2,922 | 3,308 | 3,593 | 3,895 | 4,092 |
| Revenue growth | 9.4% | 8.8% | 18.4% | 4.8% | −8.4% | 20.2% | 13.2% | 8.6% | 8.4% | 5.1% |
| Gross profit | 1,173 | 1,366 | 1,632 | 1,757 | 1,535 | 1,956 | 2,140 | 2,358 | 2,596 | 2,682 |
| Research and development | 65 | 69 | 85 | 87 | 93 | 93 | 110 | 137 | 155 | 172 |
| Operating income | 324 | 429 | 403 | 547 | 312 | 506 | 508 | 533 | 706 | 683 |
| Net income | 274 | 373 | 140 | 467 | 238 | 2,945 | 386 | 294 | 392 | 375 |
| Diluted EPS (US$) | 1.40 | 1.88 | 0.70 | 2.33 | 1.20 | 14.79 | 1.94 | 1.48 | 1.96 | 1.87 |
| Diluted shares (millions) | 196 | 198 | 199 | 200 | 198 | 199 | 199 | 199 | 200 | 200 |
| Cash flow | ||||||||||
| Cash from operations | 510 | 594 | 669 | 713 | 487 | 739 | 692 | 608 | 709 | 796 |
| Capital expenditure | 153 | 127 | 194 | 292 | 310 | 214 | 242 | 392 | 421 | 362 |
| Free cash flow | 357 | 466 | 475 | 421 | 176 | 524 | 450 | 215 | 288 | 434 |
| Dividends paid | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 |
| Share buybacks | 0 | 55 | 0 | 156 | 48 | 25 | 78 | 0 | 0 | 290 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 30 | 37 | 43 | 35 | 38 | 44 | 54 | 62 | 75 | 70 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 101 | 89 | 78 | 89 | 116 | 96 | 138 | 121 | 108 | 111 |
| Debt incl. finance leases | 1,544 | 1,173 | 2,023 | 1,263 | 1,386 | 1,398 | 2,763 | 2,569 | 2,584 | 2,505 |
| Total assets | 4,479 | 4,859 | 6,113 | 6,274 | 6,738 | 9,606 | 11,492 | 11,659 | 12,315 | 12,395 |
| Total liabilities | 1,783 | 1,683 | 2,805 | 2,646 | 2,913 | 2,664 | 4,318 | 4,108 | 4,232 | 4,156 |
| Shareholders' equity | 2,696 | 3,176 | 3,308 | 3,628 | 3,825 | 6,942 | 7,174 | 7,551 | 8,083 | 8,239 |
| Margins and ratios | ||||||||||
| Gross margin | 59.6% | 63.9% | 64.5% | 66.2% | 63.1% | 66.9% | 64.7% | 65.6% | 66.6% | 65.5% |
| Operating margin | 16.5% | 20.1% | 15.9% | 20.6% | 12.8% | 17.3% | 15.3% | 14.8% | 18.1% | 16.7% |
| Net margin | 13.9% | 17.4% | 5.5% | 17.6% | 9.8% | 100.8% | 11.7% | 8.2% | 10.1% | 9.2% |
| Free cash flow margin | 18.1% | 21.8% | 18.8% | 15.9% | 7.2% | 17.9% | 13.6% | 6.0% | 7.4% | 10.6% |
| Return on capital | 7.4% | 9.7% | 4.2% | 10.6% | 5.6% | 7.6% | 4.6% | 3.8% | 4.6% | 4.3% |
| Return on equity | 10.2% | 12.7% | 4.3% | 13.5% | 6.4% | 54.7% | 5.5% | 4.0% | 5.0% | 4.6% |
| Return on assets | 6.1% | 8.0% | 2.5% | 7.5% | 3.7% | 36.0% | 3.7% | 2.5% | 3.3% | 3.0% |
| Net debt to EBITDA | 2.8x | 1.8x | 2.9x | 1.4x | 2.1x | 1.6x | 3.1x | 2.7x | 2.3x | 2.3x |